ACTICOAT in action
Case Studies using ACTICOAT Wound Dressings
Less than a two week difference with ACTICOAT18 | After 6 weeks |
ACTICOAT used as primary dressing in conjunction with compression bandaging on a long standing venous leg ulcer. Treatment plan of twice-weekly bandage changes due to high levels of exudate
|
Wound progressing after the first dressing change
|
After 6 weeks ACTICOAT was discontinued as the wound bed was now not infected
|
A two week difference with ACTICOAT Moisture Control19 | After 4 weeks |
Type 2 diabetic with extensive partial-thickness skin loss. Wound at initial presentation after debridement. Other leg previously amputated following complications arising from infected neuropathic ulcer
|
Wound at time of dressing change
|
Diabetic Foot Clinic follow-up visit, four weeks after initial presentation
|
A two week difference - ACTICOAT Flex 320 | ALLEVYN◊ Gentle Border used as secondary dressing |
Heavily colonised malodorous surgical wound left to heal by secondary intention. Wound had been present for eight months and the patient complained of odour and discharge
|
Improvement after just two weeks using ACTICOAT Flex 3
|
Following just a few weeks, all the signs and symptoms of infection had disappeared and the wound continued to follow a normal wound healing trajectory
|
Change the outcome, take the ACTICOAT 2 WEEK CHALLENGE◊.
Apply to receive a 2 week's supply of ACTICOAT Flex* samples for appropriate use on an infected wound.
*Where possible samples will be ACTICOAT Flex, in areas where ACTICOAT Flex is not registered an alternative ACTICOAT variant may be offered.
- Kelly J. Addressing the problem of increased antibiotic resistance. Prof Nurs 2001; 17(1): 56-9
- Hamilton-Miller JMT, Shah S, Smith C. Silver sulphadiazine: a comprehensive in-vitro reassessment. Chemotherapy 1993; 39: 405-9
- Maillard J-Y and Denyer SP. 2006. Focus on Silver. EWMA JournalV6(1)
- Warriner R and Burrell R. Infection and the chronic wound - a focus on silver. Advances in Skin and Wound Care Vol 18 (Supp. 1) Oct 2005
- Chopra I. (2007) The increasing use of silver based products as antimicrobial agents: a useful development or a cause of concern. Journal of Antimicrobial Chemotherapy 59, 587-590
- Vlachou E, et al. The safety of nanocrystalline silver dressings on burns: A study of systemic absorption. Burns 2007. 33(8):979-85
- Sibbald R G, Browne A C, Coutts P, Queen D, 'A Screening Evaluation of an Ionized Nanocrystalline Silver Dressing in Chronic Wound Care'. Ostomy Wound Management 2001; 47(10): 38-4
- Gago M, et al., A comparison of three silver-containing dressings in the treatment of infected, chronic wounds. Wounds 2008; 20 (10): 273-278
- Wright JB, et al. 'Wound Management in an era of increasing bacterial antibiotic resistance: A role for topical silver treatment', American Journal of Infection Control 1998; 26(6): 572-577
- Smith & Nephew Data on File; 0810016
- Smith & Nephew Data on File; 0810017
- Hope R, et al., (2012) The in-vitro antibacterial activity of nanocrystalline silver dressings against bacteria withNDM-1 carbapenemase. Poster at EWMA, Austria, 2012.
- Smith & Nephew Data on File WRP-TW141-022
- Westain Report Ref: #971030
- World Union of Wound Healing Societies (WUWHS). Principles of best practice: Wound infection in clinical practice. An international consensus. London: MEP Ltd, 2008. Available from www.woundsinternational.com
- International consensus. Appropriate use of silver dressings in wounds. An expert working group consensus. London: Wounds International, 2012.Available from:www.woundsinternational.com
- Searle and Bielby (2010) Dressing strategies for the management of infected wounds in community wound care: impacts and implications. Poster at Wounds UK, Harrogate Nov 2010.
- Murray, S and Pardoe, A (2010) Making an Impact: Improving the patient experience using ACTICOAT Flex. Case Study Booklet
- Tongue G., Prytherch J., Harvey A. The Silver Revolution. Exeter Primary Care Trust. Poster Presentation. Wounds UK. Harrogate 2004
- Bowering K. “ACTICOAT Moisture Control. A New Clinical Option” Case study presentation. Satellite Symposium at Stuttgart (a joint meeting for ETRS, EWMA and DGfW) 2005